OGN

NYSE · Pharmaceuticals

Organon & Co

Mid-Cap Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks Highest Dividend Yield

$13.68

-0.01 (-0.07%)

As of Sep 20, 10:06 PM ET ·

Financial Highlights (FY 2026)

Revenue

6.29B

Net Income

189.08M

Gross Margin

53.3%

Profit Margin

3.0%

Rev Growth

+0.2%

D/E Ratio

11.49

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	53.3%	53.3%	28.3%	28.3%
Operating Margin	6.8%	6.2%	27.9%	29.6%
Profit Margin	3.0%	2.9%	28.0%	28.9%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	6.29B	6.27B	515.23M	479.67M
Gross Profit	3.35B	3.34B	145.97M	135.89M
Operating Income	429.91M	386.03M	143.74M	141.87M
Net Income	189.08M	169.78M	144.40M	138.60M
Gross Margin	53.3%	53.3%	28.3%	28.3%
Operating Margin	6.8%	6.2%	27.9%	29.6%
Profit Margin	3.0%	2.9%	28.0%	28.9%
Rev Growth	+0.2%	+0.2%	+11.5%	-9.2%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	1.65B	1.65B	937.97M	935.09M
Total Equity	143.92M	143.92M	1.31B	1.37B
D/E Ratio	11.49	11.49	0.71	0.68

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	587.48M	556.82M	186.20M	184.13M
Free Cash Flow	—	—	113.95M	97.08M